TBX-2400: A NEW CLASS OF CELL THERAPY
TBX-2400 is an allogeneic stem cell product being developed to improve bone marrow transplants.
The U.S. FDA has approved TBX-2400’s IND.
Treatment includes the infusion of donor hematopoietic stem cells treated with TBX-4000.
Active Phase I/II clinical trial for patients with either AML or Myelofibrosis.
US Orphan Drug Designation.
US Rare Pediatric Drug Designation.
EMA Orphan Drug Designation.
EMA Advanced Therapy Medicinal Product Designation.
IMPROVING BONE MARROW TRANSPLANTS
Composed of donor hematopoietic stem cells treated ex vivo for 1 hour with TBX-4000.
1. Blood Collection: blood is drawn from the donor in a hospital or clinic in an outpatient setting.
2. Processing: the bone marrow stem cells are separated and treated with Taiga's TBX-4000 protein.
3. Treatment: the treated cells are then given to the patient.
TBX-2400: BETTER, FASTER, AFFORDABLE
Issues with today's allogenetic BMTs